Incomes of BioMaxima co. after 2011 increased by 46.23 % as compared to the previous year. The turned net profit was equal to 988 383 PLN (235 330 EUR), which accounts for 183.36 % of the results from the previous year. It is worth mentioning that increase in income and net profit of the co. was being observed continuously during the last 9 years.
In 2009 the company has become the exclusive distributor of the unique producer of hospital glucometers – Nova Biomedical, while in August 2010 it has purchased 100 % of the assets of POLAB Ltd. from Biosigma (the Italian producer of disposable lab materials). What is more, since June 2011 BioMaxima has owned its main residence and the research-production center within the Special Economic Zone of Mielec – Subzone of Lublin. Thus, the synergistic effect of all the company activities is evident and the obtained results clearly indicate the dynamic development of BioMaxima co.
Our earned results give us a lot of satisfaction – says the chairman of BioMaxima co., Henryk Lewczuk. – It is not only because of all-time high profit increase, but also because of that our results reconfirm accuracy of our development strategy, which is based on maximal possible utilization of the science and research potential accompanied with synergy of products obtained in efficient canvassing. Having longstanding experience in the biotechnology business, we have full awareness of the great dynamics of its market and its high susceptibility to innovations. This is why we are continuously working on the maintenance of our advantages as well as the consequential market position of the BioMaxima co. emphasizes Lewczuk.
In the end of December 2011 BioMaxima co, signed a preliminary contract to purchase 100 % of Emapol Ltd. assets. The deal was worth 6.6 million PLN (1.6 million EUR). The final contract is planned to be concluded until 30th March 2012. On the 5th December 2012 BioMaxima signed a letter of intent with German company, HSG-IMIT, in terms of a development project concerning automatic integrated micro-flow analysis to be used in a specialist diagnostic platform, LabDisk. This new device enables one to conduct a set of research having just a single drop of blood. As compared to presently used analyzers and research methods, the platform utilizes from 10 up to 100 times less blood material and allows running nearly 100 different tests. Thanks to its small size, handling facility and high precision of assays the new diagnostic platform should easily find many ways of application at the diagnostic laboratories, hospitals and medical clinics.
BioMaxima co. plans to start production of the platform at its own production facility located within the Special Economic Zone. Signing of the proper contract with HDG-IMIT will take place until the 30th April 2012. Afterwards, the prototype of the LabDisk will be prepared within 3-6 months.
Translation: Anna Drzazga